Kazmierski W, Wire W S, Lui G K, Knapp R J, Shook J E, Burks T F, Yamamura H I, Hruby V J
Department of Chemistry, University of Arizona, Tucson 85721.
J Med Chem. 1988 Nov;31(11):2170-7. doi: 10.1021/jm00119a019.
A series of conformationally restricted, cyclic octapeptides containing a conformationally stable tetrapeptide sequence related to somatostatin, -Tyr-D-Trp-Lys-Thr-, as a template, were designed and synthesized with the goal of developing highly potent and selective mu opioid antagonists with minimal or no somatostatin-like activity. Three distinct structures of the peptide became targets of chemical modifications and constraints; the N- and C-terminal amino acids and the cyclic 20-membered ring moiety. Based on the conformational analysis of active and inactive analogues of the parent peptide D-Phe1-Cys2-Tyr3-D-Trp4-Lys5-Thr6-Pen7+ ++-Thr8-NH2, CTP (Kazmierski, W.; Hruby, V. J. Tetrahedron 1988, 44, 697-710), we designed analogues to include the tetrahydroisoquinolinecarboxylate (Tic) moiety as the N-terminal amino acid instead of D-Phe, since Tic can exist only as a gauche (-) or a gauche (+) conformer. In this series, the following peptides were synthesized and pharmacologically evaluated: D-Tic-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 (TCTP), D-Tic-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (TCTOP), and D-Tic-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (TCTAP). In rat brain membrane opioid radioligand binding assays, all three peptides displayed high affinity for mu opioid receptors (IC50 = 1.2, 1.4, 1.2 nM, respectively), and exceptional mu vs delta opioid receptor selectivity: 7770, 11,396, and 1060, respectively. TCTOP and TCTAP also possess exceptional mu vs somatostatin receptor selectivity: 14,574 and 28,613, respectively. In the peripheral in vitro GPI bioassay, TCTP, TCTOP, and TCTAP were highly effective antagonists of the potent mu opioid receptor agonist PL017, with pA2 = 8.69 for TCTAP, 8.10 for TCTP, and 7.38 for TCTOP. Our results show that a 10-fold higher affinity and selectivity for mu opioid receptors (in both central and peripheral studies) over delta and somatostatin receptor was gained as a result of the D-Tic1 substitution. These three peptides, TCTP, TCTOP, and TCTAP, are the most potent and selective mu opioid antagonists known. CTP has been shown to possess prolonged biological action, much longer than that of naloxone. This renders these analogues potentially useful ligands for investigating the physiological functions of the mu opioid receptor. Analogues of TCTP in which the 20-membered disulfide ring was contracted by deletion of D-Trp4, and/or Lys5, and/or Thr6 led to compounds with greatly reduced potency at the mu opioid receptor.(ABSTRACT TRUNCATED AT 400 WORDS)
设计并合成了一系列构象受限的环八肽,其含有与生长抑素相关的构象稳定的四肽序列-Tyr-D-Trp-Lys-Thr-作为模板,目的是开发具有高效和选择性的μ阿片受体拮抗剂,且具有最小或无生长抑素样活性。肽的三种不同结构成为化学修饰和限制的目标;N端和C端氨基酸以及环状20元环部分。基于母体肽D-Phe1-Cys2-Tyr3-D-Trp4-Lys5-Thr6-Pen7+ ++-Thr8-NH2(CTP,Kazmierski,W.;Hruby,V. J. Tetrahedron 1988,44,697-710)的活性和非活性类似物的构象分析,我们设计类似物,将四氢异喹啉羧酸酯(Tic)部分作为N端氨基酸而非D-Phe,因为Tic仅能以gauche(-)或gauche(+)构象存在。在该系列中,合成了以下肽并进行了药理学评价:D-Tic-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(TCTP)、D-Tic-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(TCTOP)和D-Tic-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(TCTAP)。在大鼠脑膜阿片受体放射性配体结合试验中,所有三种肽对μ阿片受体均显示出高亲和力(IC50分别为1.2、1.4、1.2 nM),以及出色的μ与δ阿片受体选择性:分别为7770、11396和1060。TCTOP和TCTAP还具有出色的μ与生长抑素受体选择性:分别为14574和28613。在体外外周GPI生物测定中,TCTP、TCTOP和TCTAP是强效μ阿片受体激动剂PL017的高效拮抗剂,TCTAP的pA2为8.69,TCTP为8.10,TCTOP为7.38。我们的结果表明,由于D-Tic1取代,对μ阿片受体(在中枢和外周研究中)的亲和力和选择性比δ和生长抑素受体高10倍。这三种肽,TCTP、TCTOP和TCTAP,是已知的最有效和选择性的μ阿片受体拮抗剂。已证明CTP具有延长的生物作用,比纳洛酮长得多。这使得这些类似物成为研究μ阿片受体生理功能的潜在有用配体。TCTP的类似物,其中20元二硫环通过缺失D-Trp4、和/或Lys5、和/或Thr6而收缩,导致在μ阿片受体处效力大大降低的化合物。(摘要截短于400字)